Compare BLSH & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLSH | CNTA |
|---|---|---|
| Founded | 2020 | 2020 |
| Country | Cayman Islands | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.1B |
| IPO Year | N/A | 2021 |
| Metric | BLSH | CNTA |
|---|---|---|
| Price | $44.19 | $39.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $51.91 | $43.17 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $64.30 | N/A |
| Revenue Next Year | $17.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.69 | $10.95 |
| 52 Week High | $74.98 | $40.26 |
| Indicator | BLSH | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 71.98 |
| Support Level | $35.21 | $39.36 |
| Resistance Level | $45.22 | $40.26 |
| Average True Range (ATR) | 2.80 | 0.15 |
| MACD | 0.24 | -0.41 |
| Stochastic Oscillator | 61.42 | 44.16 |
Bullish is an institutionally focused global digital asset platform focused on providing market infrastructure and information services. Its objective is to provide mission critical products and services that are designed to help institutions grow their businesses, empower individual investors, and drive the adoption of stablecoins, digital assets, and blockchain technology. It expanded its product offering to provide trusted insights, authoritative news, data, indices and transparent analysis to the digital assets industry while facilitating partnerships, investment opportunities, and community engagement through its flagship Consensus conference.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.